Retatrutide Research Record: Hepatic Impairment

At a glance

• Review question / What do peer-reviewed and registered retatrutide studies establish about hepatic Impairment?
• Best evidence / peer-reviewed trial reports and registry records
• Evidence snapshot / 2026-08-09
• Commercial status / no FDA-approved product or ordinary retail supply
• HealthRX role / independent educational review; no retatrutide product or treatment offer

Direct answer

The public evidence base includes early-phase pharmacology records, randomized phase 2 reports, phase 3 registry records, and a published phase 3 type 2 diabetes report. For hepatic Impairment, the first task is to identify whether the topic was a prespecified endpoint, an eligibility factor, a subgroup, or only a hypothesis.

The wording here is deliberately evidence-specific. “A study exists,” “a registry lists a site,” and “a paper reports an endpoint” are different statements from “a product is approved,” “a treatment works,” or “a person should use it.” This page makes only the first type of statement and links the controlling source.

Evidence map for hepatic Impairment

How HealthRX evaluated this question

Evidence strength depends on the question. Mechanism studies can show receptor activity; phase 1 records can characterize pharmacology; randomized trials can test prespecified endpoints; registries document plans and status. None of these source types should be asked to answer a broader question than its design supports.

For this page, HealthRX asked: (1) Is hepatic Impairment named in the protocol or publication? (2) Was it a prespecified endpoint, eligibility factor, subgroup, or only background context? (3) Is the record complete, current, and peer reviewed? (4) Does an FDA action or approved label exist? That sequence prevents a research observation from being rewritten as a product claim.

Evidence checks specific to this record

Missing-data handling

Check participant flow, discontinuations, missing measurements, and the estimand used for analysis. For hepatic Impairment, a result based only on completers may answer a different question from an analysis that accounts for everyone randomized.

Exposure context

Document formulation, assigned regimen, treatment duration, background care, and protocol monitoring. Evidence about hepatic Impairment belongs to that controlled exposure context; it should not be generalized to an unverified product or to use outside a registered study.

Question-to-source fit

Use the source that can actually answer the question. FDA records control regulatory status, registries document study plans, protocols define methods, and publications report analyses. For hepatic Impairment, a lower-level source should not be used to make a higher-level claim.

Replication threshold

One record can establish that a question was studied. Confidence in hepatic Impairment grows when methods and findings are reproduced in an appropriate population, reported completely, and reconciled with the broader evidence base. Replication is different from repetition of the same dataset.

Multiplicity control

When many doses, time points, subgroups, or outcomes are examined, chance findings become more likely. A review of hepatic Impairment should identify which analyses were prespecified and how the statistical plan addressed multiple testing before treating a signal as durable evidence.

What remains unresolved

A study's existence does not establish an approved indication, overall safety or effectiveness, a public-use instruction, or a conclusion beyond its enrolled population and prespecified endpoints.

The source hierarchy also matters. An FDA action controls approval status. ClinicalTrials.gov controls the public registry record. A peer-reviewed report can describe study methods and observations. A press release, seller page, social post, search result, or anecdote cannot replace those sources.

What evidence could change the answer

Confidence would increase with a prespecified hepatic Impairment measure, transparent analysis methods, complete reporting, independent replication where applicable, and regulatory review.

Any new result should be read with its protocol and statistical analysis plan. Important checks include enrollment, prespecified outcomes, follow-up duration, missing-data handling, multiplicity, participant flow, sponsor involvement, and whether the finding has undergone peer review and regulatory review.

Current federal and commercial status

Retatrutide remains investigational. No retatrutide product is FDA-approved for any indication or available through ordinary commercial prescription or retail sale. FDA states that retatrutide cannot be used in compounding under federal law. HealthRX does not offer it. FDA's current statement says retatrutide is not a component of an FDA-approved drug and cannot be used in compounding under federal law. A ClinicalTrials.gov study or eligibility-limited expanded-access record is not commercial approval, ordinary prescribing, retail availability, or evidence that HealthRX offers the investigational substance.

Federal regulation distinguishes scientific exchange from promotion: it does not restrict full exchange of scientific information, but it does restrict representing an investigational drug as safe or effective in a promotional context and precludes commercialization before approval.

Source selection and review method

HealthRX reviewed primary or primary-index sources current to 2026-08-09: ClinicalTrials.gov hepatic-function record NCT05916560; Jastreboff et al., phase 2 obesity trial report; Rosenstock et al., phase 2 type 2 diabetes trial report; Bajaj et al., TRANSCEND-T2D-1 phase 3 report; FDA status statement for unapproved GLP-1 drugs; 21 CFR 312.7, Promotion of investigational drugs. Sources were selected because they control regulatory status, register a study, or index a peer-reviewed clinical report. The review reports study design and evidence limits without reproducing promotional outcome claims or converting protocols into patient instructions.

Frequently asked questions

›What is established about hepatic Impairment?

Public sources document study designs, enrolled populations, prespecified endpoints, and regulatory status. They do not establish an FDA-approved indication, public-use instruction, or conclusion beyond those records.

›Does this research mean retatrutide is approved or publicly offered?

No. Retatrutide remains investigational, is not available through ordinary commercial prescription or retail sale, cannot be used in compounding under federal law, and is not offered by HealthRX.

›How can readers verify this review?

Use the linked FDA, eCFR, PubMed, and ClinicalTrials.gov records. Check the source date, study status, population, endpoint definitions, sponsor, and whether results have been peer reviewed.

References

1. ClinicalTrials.gov. Retatrutide hepatic-function study record. 2026. https://clinicaltrials.gov/study/NCT05916560
2. Jastreboff AM, Kaplan LM, Frias JP, et al. Phase 2 retatrutide obesity trial report. New England Journal of Medicine. 2023. https://pubmed.ncbi.nlm.nih.gov/37366315/
3. Rosenstock J, Frias J, Jastreboff AM, et al. Phase 2 retatrutide type 2 diabetes trial report. The Lancet. 2023. https://pubmed.ncbi.nlm.nih.gov/37385280/
4. Bajaj HS, Welch M, Shah P, et al. TRANSCEND-T2D-1 phase 3 trial report. The Lancet. 2026. https://pubmed.ncbi.nlm.nih.gov/42250575/
5. U.S. Food and Drug Administration. FDA status statement for unapproved GLP-1 drugs. 2026. https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
6. Electronic Code of Federal Regulations. 21 CFR 312.7, Promotion of investigational drugs. 2026. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-312/subpart-A/section-312.7